 |
|
Donepezil Therapy in Clinical Practice
A Randomized Crossover Study
Steven M. Greenberg, MD, PhD;
Marsha K. Tennis, RN;
Laura B. Brown;
Teresa Gomez-Isla, MD, PhD;
Douglas L. Hayden, MA;
David A. Schoenfeld, PhD;
Katie L. Walsh;
Claire Corwin, PA-C;
Kirk R. Daffner, MD;
Pamela Friedman;
Mary-Ellen Meadows, PhD;
Reisa A. Sperling, MD;
John H. Growdon, MD
Arch Neurol. 2000;57:94-99.
Objective To determine the efficacy of donepezil hydrochloride for the treatment of Alzheimer disease in patients drawn from clinical practice.
Design Two-center, randomized, placebo-controlled, double-masked crossover study.
Setting Memory disorders units at Massachusetts General and Brigham and Women's hospitals, Boston.
Patients Sixty individuals (30 men and 30 women; mean ± SD age, 75.0 ± 9.5 years) with probable Alzheimer disease and scores of 20 or less on the information-memory-concentration subscale of the Blessed Dementia Scale.
Interventions Placebo wash-in, followed in randomized sequence by (1) donepezil hydrochloride therapy, 5 mg/d, for 6 weeks, followed by placebo washout for 6 weeks and (2) placebo treatment for 6 weeks.
Primary Outcome Measure Change in Alzheimer's Disease Assessment Scale cognitive subscale scores from the beginning to the end of the two 6-week treatment periods.
Results Among patients completing treatment and testing for both periods (n = 48), subscale scores improved (mean ± SEM) 2.17 ± 0.98 points (95% confidence interval, 0.20-4.10 points) during donepezil therapy relative to placebo therapy (P = .04). Scores returned toward baseline within 3 weeks of drug washout. There was no associated change in caregiver-rated global impression (donepezil vs placebo: proportion improved, 0.24 vs 0.22; proportion worsened, 0.27 vs 0.35; P = .34) or on specific tests of explicit memory or verbal fluency. Contrary to studies with tacrine, the presence of the apolipoprotein E  4 allele did not predict donepezil treatment failure. Most common adverse events related to donepezil therapy were nausea (5 patients), diarrhea (3 patients), and agitation (3 patients). Serious events possibly related to drug use were seizure, pancreatitis, and syncope (1 patient each).
Conclusion This independent confirmation of data from phase 3 trials suggests that donepezil therapy modestly improves cognition in patients with Alzheimer disease who are encountered in clinical practice.
From the Departments of Neurology, Partners HealthCare Inc of Massachusetts General Hospital (Drs Greenberg, Gomez-Isla, Schoenfeld, and Growdon, and Mss Tennis, Brown, and Walsh and Mr Hayden) and Brigham and Women's Hospital (Mss Corwin and Friedman and Drs Daffner, Meadows, and Sperling), Harvard Medical School, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Amyloid {beta}-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy
Minkeviciene et al.
J. Neurosci. 2009;29:3453-3462.
ABSTRACT
| FULL TEXT
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease
Bordier et al.
Europace 2007;9:829-834.
ABSTRACT
| FULL TEXT
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
Kaduszkiewicz et al.
BMJ 2005;331:321-327.
ABSTRACT
| FULL TEXT
Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease?
Hashimoto et al.
Am. J. Psychiatry 2005;162:676-682.
ABSTRACT
| FULL TEXT
Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer's disease
Holroyd-Leduc
Evid. Based Med. 2005;10:15-15.
FULL TEXT
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
Lanctot et al.
CMAJ 2003;169:557-564.
ABSTRACT
| FULL TEXT
Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force
Boustani et al.
ANN INTERN MED 2003;138:927-937.
ABSTRACT
| FULL TEXT
Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors
Bordier et al.
Europace 2003;5:429-431.
ABSTRACT
| FULL TEXT
Goal setting and attainment in Alzheimer's disease patients treated with donepezil
Rockwood et al.
J. Neurol. Neurosurg. Psychiatry 2002;73:500-507.
ABSTRACT
| FULL TEXT
Assessment of low-flow CSF drainage as a treatment for AD: Results of a randomized pilot study
Silverberg et al.
Neurology 2002;59:1139-1145.
ABSTRACT
| FULL TEXT
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:708-712.
ABSTRACT
| FULL TEXT
Frontiers in Neuropharmacotherapy Part I: Alzheimer's Disease and Epilepsy
Chappell and Cohen
Journal of Pharmacy Practice 2002;15:195-220.
ABSTRACT
Donepezil for memory dysfunction in schizophrenia
Howard et al.
J Psychopharmacol 2002;16:267-270.
ABSTRACT
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Deleu et al.
Neurology 2002;58:835-836.
FULL TEXT
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan et al.
Neurology 2001;57:467-473.
ABSTRACT
| FULL TEXT
Care of older people: Mental health problems
Burns et al.
BMJ 2001;322:789-791.
FULL TEXT
Donepezil in the Treatment of Alzheimer Disease
Deleu et al.
Arch Neurol 2000;57:1380-1380.
FULL TEXT
Adverse effects associated with the use of donepezil in general practice in England
Dunn et al.
J Psychopharmacol 2000;14:406-408.
ABSTRACT
|
